Tamoxifen for the Prevention of Breast Cancer in High-Risk Women
Status:
Active, not recruiting
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
The International Breast Cancer Intervention Study I (IBIS-I) was designed to investigate the
use of tamoxifen in preventing breast cancer in women with a higher risk of developing the
disease. Recruitment of women to IBIS-I ended in March 2001 and it recruited 7154 women from
36 centres in 9 countries. The results of the study showed that tamoxifen reduced the
incidence of breast cancer by one third in these high risk women but with some serious side
effects. IBIS-II was designed to continue the work started in IBIS-I by examining the role of
anastrozole in the prevention of breast cancer which we hope will reduce breast cancer by
even more than tamoxifen with less serious side effects.
Phase:
Phase 3
Details
Lead Sponsor:
Institute of Cancer Research, United Kingdom Queen Mary University of London